 "Bharat Biotech to have phase 3 efficacy data for Covaxin in 2 weeks")
Krishna Ella, chairman and managing director of Bharat Biotech, said the company would come out with the phase 3 efficacy data for Covaxin in two weeks. Speaking at a webinar, Ella said that had the company combined phase 2 and 3 studies, the efficacy data could have been available sooner.
Covaxin, the indigenous vaccine developed by Bharat Biotech and the Indian Council of Medical Research (ICMR), received a nod from the Indian drug regulator to be used to vaccinate health care and frontline workers, under clinical trial mode.
The restricted emergency use allowed by the regulator was based on phase 2 safety and immunogenicity studies, as well as data from monkey trials. Ella also said the intra-nasal vaccine candidate was set to start phase 1 trials later this week.
Covaxin, the indigenous vaccine developed by Bharat Biotech and the Indian Council of Medical Research (ICMR), received a nod from the Indian drug regulator to be used to vaccinate health care and frontline workers, under clinical trial mode.
The restricted emergency use allowed by the regulator was based on phase 2 safety and immunogenicity studies, as well as data from monkey trials. Ella also said the intra-nasal vaccine candidate was set to start phase 1 trials later this week.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%